Startup biotechs run on money and science. When communication between finance pros and scientists gets lost in translation, cash runways tend to truncate. Here, Athersys CFO Ivor Macleod draws light on a problem inherent to — but not often directly addressed by — new and emerging biotech organizations.
When a new product, technology, or supplier is selected during the development and design phase of the biological manufacturing process, manufacturers must assess the supplier’s own supply chain and beyond.
By Jon Best, Jeff Tremain, Ted Tharp, and Gene Wloch,AbbVie
Aseptic fill/finish manufacturing is one of the final, but crucial, steps between biopharmaceutical development and patient care, and it's especially critical for highly valuable biologics drug substances.
By Chantale G. Robles,Grifols Recombinant Protein CDMO Services
The result of regulatory compliance with quality standards is binary, but the processes employed to get there don't need to be rigid, inefficient, and expensive. Learn how innovation drives efficiencies.
This webinar serves as an overview of key aspects associated with pDADMAC flocculation implementation, including data for cleanability of stainless-steel surfaces soiled with pDADMAC flocculated cell culture.
Sutro Biopharma’s CTO, Dr. Shabbir Anik, has contributed to 15 INDs and 10 NDAs, making him a great choice to sit down with for a chat with Business Of Biotech about the mechanics of GMP and chemistry, manufacturing, and controls (CMC) strategies in emerging biopharma enterprises. Listen now and subscribe so you never miss an episode.